Drug Delivery Technologies Market Analysis 2026

Additional Insights of Drug Delivery Technologies Market

Regulation And Guidelines for the Drug Delivery Technologies Market

• North America
• Europe
• Asia Pacific
• South America
• Middle East
• Africa

Regulations for drug delivery devices are designed to ensure their safety, effectiveness, and quality throughout development, manufacturing, and post-market use. These devices, often classified as combination products (drug and device), must comply with stringent requirements set by regulatory authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). The FDA regulates these products through its Office of Combination Products, requiring comprehensive testing, including design verification, validation, and risk management to demonstrate that the device performs reliably and safely with the drug it delivers. In Europe, the Medical Device Regulation (MDR) imposes rigorous conformity assessment procedures, especially under Article 117, which mandates additional scrutiny and involvement of Notified Bodies for drug-device combinations. Manufacturers must provide detailed technical documentation, clinical evidence, and ensure compliance with quality systems standards. These regulatory frameworks, while complex, aim to protect patient safety, promote innovation, and facilitate market access for advanced drug delivery technologies.

Conferences and Events in Drug Delivery Technologies Market

Pre-Filled Syringes and Injectable Drug Devices Conference 2025

January 14–15, 2025: Nemera is proud to participate as an exhibitor at the upcoming Pre-Filled Syringes and Injectable Drug Devices Conference 2025, taking place from January 14–15. As part of SMi’s renowned injectables event series, this 14th annual conference will delve into recent advancements in combination product delivery systems. Key themes will include the industry's strategic response to the postponed EU Medical Device Regulation (EU MDR), insights gained from the global pandemic, and collaborative approaches among pharma companies, device developers, and regulators to foster future innovation.

As a global leader in drug delivery device solutions, Nemera views this event as a valuable opportunity to showcase its expertise—particularly in inhalation and nasal delivery systems—while engaging with customers and industry professionals. The event provides a platform to gather industry insights and explore new ways to improve Nemera’s offerings for both clients and patients. Featured products will include Safe'n'Sound 1mL and 2.25mL, reusable and disposable pens, and the Symbioze platform. Representing Nemera at the event will be Vincent Delfini, Sales Director, and Cécile Gross, Marketing Category Manager – Parenteral.

(Source:https://www.nemera.net/events/pfs-2025/)

Patent Analysis

(Source:https://patents.google.com/patent/US9061097B2/en)

Approved Drug Delivery Technologies Market

(Source:https://www.drugdeliverybusiness.com/medtronic-next-gen-insulin-pumps-coming/)

(Source:https://www.pharmaceutical-technology.com/analyst-comment/fda-approval-medtronic-inpen-app/?cf-view)

Pricing Analysis of the Drug Delivery Technologies Market

The pricing of drug delivery technologies varies significantly due to factors such as device complexity, technological innovation, clinical development duration and costs, and broader market dynamics. These technologies, which often combine pharmaceutical formulations with advanced engineering (e.g., smart inhalers, implantable, autoinjectors), follow pricing principles similar to those for new drug entities, including capitalized R&D expenses and the costs of failed development attempts. While some studies factor in opportunity costs and tax implications, others focus solely on direct expenditures, leading to varying cost models. Despite these differences, all research points to a consistent rise in development costs driven by stricter safety regulations, trial complexity, and innovation demands. However, improving trial efficiency and success rates presents an opportunity to reduce development costs and, consequently, market prices. In real-world practice, pricing reflects a mix of R&D investments, manufacturing costs, intellectual property, and market exclusivity. While some products have faced criticism for pricing that exceeds production costs, newer technologies often command premium prices due to their clinical value and innovation. Moving forward, aligning pricing with value-based care and increasing transparency around development costs will be essential to ensure these technologies remain both impactful and accessible.

(Source:https://www.wisdomlib.org/uploads/journals/wjpr/volume-6,-may-issue-5_6921.pdf)

Value chain analysis of the Drug Delivery Technologies Market

The development of drug delivery devices (DDDs) begins with Research & Development (R&D), focusing on designing innovative and safe technologies such as injectables or combination products. This stage involves material selection, prototype creation, and compatibility studies to ensure device efficacy and patient usability. Given the classification of DDDs under the Medical Device Regulation (MDR) as combination products (Article 1(9)), developers must plan early for regulatory compliance.

The Regulatory Strategy and Approval phase is critical, as DDDs can be integral (single-use or reusable) or non-integral, each subject to different pathways. Integral devices typically require a single marketing authorization application (MAA) under Directive 2001/83/EC, with notified body (NB) opinions focused on device compliance with General Safety and Performance Requirements (GSPR). Non-integral devices usually demand two submissions: one for the medicinal product and a separate technical dossier for the device, which must be CE-marked by an NB.

Next, Manufacturing involves stringent quality control under Good Manufacturing Practices (GMP), ensuring device sterility, functionality, and consistency at scale, while complying with both medicinal and medical device manufacturing standards.
During Packaging and Labeling, devices must meet regulatory demands to maintain sterility and provide clear, compliant user instructions and safety information, especially vital for combination products.
The Marketing and Distribution phase integrates regulatory approvals, market analysis, and logistics management, including cold chain requirements, if necessary, to ensure product availability aligned with healthcare provider and patient needs.
Finally, Customer Support and Training promote correct device usage to maximize therapeutic outcomes, while Post-Market Monitoring and Innovation ensure ongoing safety surveillance, regulatory compliance, and iterative improvements in response to real-world feedback

(Source:https://www.nemera.net/wp-content/uploads/2021/06/Alira-Health-MassMedic-Drug-Delivery-Systems-Industry-Outlook-March-2021.pdf)

Government Investment and Program for the Global Biosimilar Drugs

The U.S. government, through funding from the National Institute of Biomedical Imaging and Bioengineering (NIBIB), is investing significantly in the development of advanced drug delivery technologies aimed at enhancing patient care, improving treatment outcomes, and reducing healthcare burdens. These research efforts are broadly focused on two key areas: routes of drug delivery and delivery vehicles, each with innovative approaches to solve existing challenges in medication administration.

In terms of delivery methods, NIBIB supports the development of microneedle patches—painless, dissolvable patches designed for easy and needle-free vaccine delivery through the skin. These patches eliminate the need for refrigeration and professional administration, making them especially valuable in underserved or remote communities. Additionally, researchers are working on robotic pills that offer a less invasive alternative to self-injections. These ingestible devices can deliver complex biological drugs directly into the stomach lining, potentially replacing injections for conditions like diabetes and Crohn’s disease.

On the other hand, advancements in delivery vehicles are also being prioritized. NIBIB-funded scientists are developing nanoparticle systems for gene therapy in treating eye diseases such as macular degeneration. These nanoparticles can carry larger genetic material and evade immune detection, offering improved therapeutic outcomes. Another promising technology involves creating neutrophil-inspired nanovesicles to deliver anti-inflammatory drugs directly to the lungs, particularly for conditions like acute respiratory distress syndrome (ARDS). These biologically inspired systems aim to reduce inflammation more effectively and target specific tissues with higher precision. Through these initiatives, federal investment is helping accelerate the translation of innovative drug delivery research into real-world clinical solutions

(Source:https://www.nibib.nih.gov/sites/default/files/2022-10/Fact-Sheet-Drug%20Delivery%20Systems-July2022.pdf)

Unmet Needs of Global Drug Delivery Technologies Market

Drug delivery systems face significant challenges due to biological barriers that impede the effective delivery of therapeutic agents to specific sites within the body. Among these, the blood-brain barrier (BBB) and mucosal barriers are particularly critical obstacles. The BBB functions as a highly selective barrier that regulates the entry of molecules into the central nervous system, protecting brain homeostasis. However, this selective permeability limits the passage of many medications intended to treat neurological disorders such as brain tumors and Alzheimer’s disease. Overcoming the BBB remains a major challenge, necessitating innovative strategies such as targeted delivery methods and nanoparticle-based drug carriers to facilitate drug transport across this barrier.

Similarly, mucosal barriers lining the gastrointestinal, respiratory, ophthalmic, and genitourinary tracts pose challenges for drug absorption and distribution. These barriers can reduce the effectiveness of topical treatments, mucosal vaccines, and orally administered drugs. To address these issues, approaches including mucoadhesive nanoparticles, penetration enhancers, and advanced drug delivery systems are being developed to improve drug absorption across mucosal surfaces. Overcoming these biological hurdles requires multidisciplinary research and the creation of cutting-edge delivery technologies that maintain therapeutic efficacy without causing adverse side effects. Addressing these barriers is essential for advancing the treatment of numerous diseases and improving patient outcomes.

(Source:https://ijcrt.org/papers/IJCRT24A3053.pdf)

Competitive Landscape of Drug Delivery Technologies Market

In April 2024, Roche declared that the Phase III STARGLO trial achieved its main objective, which was long-term survival. A longer life span was observed in patients with returned or resistant (R/R) lymphoma of the large B cells (DLBCL) that had already undergone one round of treatment and were not eligible for an autologous stem cell transplant when given the combination of Columvi (glofitamab) using the drugs gemcitabine and treatment with (GemOx) instead of MabThera/Rituxan (rituximab) with GemOx.

(Source:https://www.roche.com/media/releases/med-cor-2024-04-15)

Established Market Players

• BD
• West Pharmaceutical Services 
• Nolato AB
• Phillips-Medi size 
• SHL Medical
• Sanofi Pharmaceutical
• Others

Established drug delivery device companies like BD, West Pharmaceutical Services, Nolato AB, Phillips-Medisize, and SHL Medical hold a strong market presence built on decades of experience, global manufacturing networks, and deep partnerships with pharmaceutical companies. Their broad product portfolios include proven technologies such as auto-injectors, prefilled syringes, inhalers, and wearable injectors, supported by high-volume manufacturing capabilities and robust quality systems. These companies benefit from strong brand reputations, regulatory expertise, and reliable supply chains, allowing them to efficiently serve a wide range of drug delivery needs worldwide. However, their large scale and operational complexity can sometimes slow adoption of disruptive, digital, and smart drug delivery innovations

Emerging Market Players

• Gerresheimer AG
• Aptar Pharma
• Teva Pharmaceuticals 
• 3M Drug Delivery Systems 
• Others

The emerging players like Gerresheimer AG, Aptar Pharma, Teva Pharmaceuticals, and 3M Drug Delivery Systems are rapidly expanding through innovation, acquisitions, and strategic collaborations with biotech and digital health firms. They focus heavily on next-generation drug delivery technologies such as connected devices, IoT integration, and specialty delivery systems including ophthalmic and transdermal solutions. These companies are agile, embracing patient-centric designs and digital health trends to differentiate themselves in the market. While they face challenges in scaling manufacturing and navigating regulatory landscapes, their ability to quickly adapt and innovate positions them well to meet evolving industry demands and compete against established leaders.

Recent Developments

October 13, 2021: BD (Becton, Dickinson and Company) announced the launch of the BD SCF Premium Coat Plunger Stopper in partnership with Aptar Pharma, a global leader in drug delivery solutions and services. The BD SCF Premium Coat Plunger Stopper addresses the need of pharmaceutical companies to de-risk drug development and support time to market while improving operational efficiencies and reducing stopper-related quality issues.
https://aptar.com/wp-content/uploads/2021/10/2021-10-13-BD-Launches-Plunger-Stopper-in-Partnership-with-Aptar-Pharma-to-Enhance-Biologic-Drug-Delivery.pdf

January 25, 2022: West Pharmaceutical Services, Inc. Collaborated with Corning and to enable advanced drug containment and delivery system solutions. By combining West's industry-leading Nova Pure components, with Daikyo Flurotec coating technology, and Corning's Valor Glass and Velocity Vials, the strategic collaboration will enable new, advanced pharmaceutical packaging solutions. The collaboration optimizes the materials science and manufacturing expertise of both companies to help bio-pharma producers navigate the complex regulatory environment and mitigate risk in bringing drugs to market. This partnership and investment enable the development and industry-leading solutions that enhance patient safety, increase quality and reliability in highly regulated markets, and ensure greater capacity for life-saving drugs.

(Source:https://investor.westpharma.com/news-releases/news-release-details/west-announces-landmark-collaboration-corning-pharmaceutical)

Market Strategies by the Players

Product Launch Strategies:

Successful launches focus on clear value propositions, regulatory approvals, and market education. Early engagement with healthcare professionals and key opinion leaders helps build trust and adoption. Pilot studies and real-world evidence demonstrations support marketing claims. Leveraging digital marketing, educational campaigns, and patient advocacy groups increases awareness. Phased launches, starting with targeted markets or patient populations, allow for controlled scaling and feedback incorporation.

For instance, July, 2022, the Sanofi collaborated with DCA Design International Ltd. and launched the first reusable insulin pen injector proving that sustainable medicine delivery devices gain ground.In 2021 Sanofi has launched this innovative product in India, a country in which the International Diabetes Federation estimates that 77 million people live with diabetes.

(Source:https://globaldesignnews.com/dca-and-sanofi-team-up-and-launch-the-first-reusable-insulin-pen-injector-proving-that-sustainable-medicine-delivery-devices-gain-ground)

Partnership Strategies:

Collaborations with pharmaceutical companies, medical device manufacturers, and technology firms accelerate development and distribution. Partnerships can include co-development agreements, licensing deals, or joint ventures to combine expertise, share costs, and access established sales channels. Alliances with healthcare providers and payers ensure reimbursement pathways and better market access. Engaging contract manufacturing organizations (CMOs) optimizes production efficiency.

Investment Strategies:

Securing funding through venture capital, strategic investors, or government grants is crucial for R&D and commercialization phases. Demonstrating strong intellectual property, clinical validation, and market potential attracts investors. Staged financing aligned with milestones reduces risk. Additionally, forming partnerships with industry leaders can provide both capital and market credibility. Long-term investment planning accounts for regulatory timelines and scaling needs. On July 6, 2025, the Navamedic ASA recently announced its plan to acquire the business operations of Norwegian-based DNE Pharma for up to USD 21.94 Million. While this acquisition immediately strengthens Navamedic’s presence in the Nordic pharmaceutical market.

(Source:https://pharmajobspost.in/%F0%9F%8C%8D-market-expansion-potential-can-navamedic-scale-dne-pharmas-nasal-delivery-products-beyond-norway)

SY

Supriya Yadav Verified Analyst

Research Analyst at Cognitive Market Research · Cognitive Market Research

Supriya is a Team Lead at Cognitive Market Research & Consulting, leading research initiatives and strategic intelligence projects across the Healthcare, Pharmaceuticals, and Medical Devices & Consumables sectors. With more than two years of experience in market research and data analysis, she plays a key role in helping organizations navigate complex healthcare ecosystems, identify emerging opportunities, and make informed business decisions through data-driven insights and market intelligence.

Combining expertise in both primary and secondary research methodologies with a strong academic foundation in Marketing and Finance, Supriya oversees the execution of market assessments, competitive intelligence studies, forecasting models, stakeholder interviews, trend analysis, and custom consulting engagements. She collaborates with healthcare providers, pharmaceutical manufacturers, medical device companies, industry experts, and other key stakeholders to gather firsthand market perspectives while validating findings through extensive  research. Her ability to interpret clinical, commercial, and market data enables clients to better understand industry developments, regulatory influences, innovation trends, and competitive dynamics.

In her leadership role, she manages end-to-end research projects and guides cross-functional teams in delivering high-quality market reports, consulting solutions, and strategic studies. Her expertise in market estimation, forecasting, and analytical modeling helps organizations evaluate market potential, assess growth opportunities, strengthen competitive positioning, and support strategic planning initiatives. By transforming complex healthcare and life sciences data into actionable business intelligence, she enables clients to make confident decisions in rapidly evolving market environments.

Driven by a passion for healthcare innovation and continuous professional development, Supriya remains committed to staying ahead of industry trends, technological advancements, and changing market conditions. Her leadership, analytical mindset, and dedication to research excellence help organizations mitigate risks, capitalize on emerging opportunities, and achieve sustainable growth across the global healthcare and life sciences landscape.

Read more

LinkedIn Profile Book a free Consultation